Physician profile
Mitchell David Ross
NPI 1275995540
$2,509.02
in general payments reported to CMS, 2019-2025
46 companies · $789 in 2025
The $789 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $252 · 2022: $264 · 2023: $447 · 2024: $757 · 2025: $789.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,954 · Education: $39.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.18 |
| Education | $39.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $241.69 | 2023-2025 | Tecvayli, Talvey, Darzalex |
| Novartis Pharmaceuticals Corporation | $176.89 | 2023-2025 | |
| Epizyme, INC. | $174.40 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $147.55 | 2022-2025 | Enhertu, Tagrisso |
| Incyte Corporation | $146.55 | 2021-2025 | Monjuvi, Monjuvi |
| Daiichi Sankyo INC. | $113.91 | 2022-2025 | Enhertu |
| Genzyme Corporation | $104.37 | 2024-2025 | |
| Foundation Medicine, INC. | $98.50 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $96.49 | 2023-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $91.31 | 2023-2025 | Keytruda, Welireg |
| Astellas Pharma US INC | $79.99 | 2022 | |
| Genentech USA, INC. | $60.17 | 2023-2025 | Itovebi, Gavreto, Alecensa |
| Array Biopharma INC | $53.90 | 2022-2024 | Braftovi, Lorbrena, Xalkori |
| Takeda Pharmaceuticals U.S.A., INC. | $52.86 | 2025 | Hyqvia, Ninlaro, Fruzaqla |
| Rigel Pharmaceuticals, INC. | $51.55 | 2023-2024 | Tavalisse, Rezlidhia |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.